Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer | Zendy

Ignace Vergote | Zendy; Agustin A. García | Zendy; John P. Micha | Zendy; Charles H. Pippitt | Zendy; Johanna C. Bendell | Zendy; Daniel L. Spitz | Zendy; Nicholas Reed | Zendy; G. Dark | Zendy; Paula M. Fracasso | Zendy; Emad Ibrahim | Zendy; Vincent Armenio | Zendy; Linda Duska | Zendy; Chris Poole | Zendy; Christine Gennigens | Zendy; Luc Dirix | Zendy; Abraham C.F. Leung | Zendy; Carol Zhao | Zendy; Raoudha SoufiMahjoubi | Zendy; Gordon Rustin | Zendy

Open Access

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Author(s) -

Ignace Vergote,

Agustin A. García,

John P. Micha,

Charles H. Pippitt,

Johanna C. Bendell,

Daniel L. Spitz,

Nicholas Reed,

G. Dark,

Paula M. Fracasso,

Emad Ibrahim,

Vincent Armenio,

Linda Duska,

Chris Poole,

Christine Gennigens,

Luc Dirix,

Abraham C.F. Leung,

Carol Zhao,

Raoudha SoufiMahjoubi,

Gordon Rustin

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.45.1278

Subject(s) - medicine , neutropenia , nausea , adverse effect , irinotecan , clinical endpoint , tolerability , gastroenterology , ovarian cancer , refractory (planetary science) , randomized controlled trial , oncology , cancer , surgery , chemotherapy , colorectal cancer , physics , astrobiology

Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two dosing schedules of etirinotecan pegol in patients with platinum-resistant/refractory ovarian carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research